Testing AN8025 in Advanced Solid Cancers
Part of Cancer clinical trials.
This early-stage trial tests a new drug called AN8025 in people with advanced solid tumors (cancers that started in organs or tissues). The study aims to find the right dose and see if it helps patients whose cancers have grown despite other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to give informed consent
- Have advanced or metastatic solid cancer that has progressed after standard treatments or you cannot tolerate them
- Be in good overall health (ECOG performance status 0–1) with at least 12 weeks life expectancy
- Have adequate blood cell counts and organ function based on recent lab tests
- Provide a tumor tissue sample (archival or newly obtained biopsy) for testing
- Have recovered from previous cancer treatments and not be enrolled in another cancer study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug called KH801 for people with advanced solid tumors (cancers that have spread) that haven't been helped by other treatments. The goal is to see if it is safe and how well it works.
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Hear when a new Advanced Solid Tumor (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.